FDALive.com Internet Privacy Statement
Protecting your privacy is important to us. We hope the following statement will help you understand how FDALive.com collects, uses and safeguards the personal information you provide to us on our site.
When visitors access the FDALive.com Web site, they are free to browse anonymously. We do not track visitors e-mail, pages browsed, etc. When you register for the FDALive.com on-line service, you can be assured that your privacy is safeguarded on our secure site. We have implemented the use of Secure Socket Layer (SSL) technology to provide the highest level of Internet security available today. The SSL protocol encrypts your personal information being transferred over the Internet.
To register for the FDALive.com on-line services, personal data will be requested for the sole purpose of setting up an account. This information will include name, company name, address, e-mail, telephone number and payment information. This information will be used to provide the FDALive.com services, for billing purposes, to correspond with you about your order and to inform you of new FDALive.com services.
FDALive.com guarantees that we will not sell your personal information to any other entities.
Declining E-Mail Offers:
We understand that some of our members may prefer to not receive e-mail announcements from FDALive.com regarding new or enhanced services. To request that your e-mail information be removed from any FDALive.com marketing activities, simply access your FDALive account and Select the "Edit Account" option. Near the bottom of the screen, opt-out of future e-mails by de-selecting the checkbox and then "Update" your membership.
Please direct any questions you may have regarding our policies to support@FDALive.com.
- Oncologic Drugs Advisory Committee
Meeting Date: 2/9/21-2/9/21
The committee will discuss supplemental biologics license application (sBLA) 125514/s-089, for KEYTRUDA (pembrolizumab), submitted by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. The proposed indication (use) for this product is for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
|Location:||Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.||Related News Links:||Not Available|